Recent developments in prion immunotherapy

Current Opinion in Immunology

Volumn 16, Issue 5, 2004, Pages 594-598

  Heppner, Frank L ^a   Aguzzi, Adriano ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PRION PROTEIN; VACCINE;

B LYMPHOCYTE; BIOASSAY; CELL SURFACE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; IN VITRO STUDY; NONHUMAN; PRION DISEASE; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ANTIBODIES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; PRION DISEASES; PRPC PROTEINS; PRPSC PROTEINS;

EID: 4444298682     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2004.07.008     Document Type: Review

References (40)

1. S.B. Prusiner Novel proteinaceous infectious particles cause scrapie Science 216 1982 136 144
2. B. Oesch, D. Westaway, M. Walchli, M.P. McKinley, S.B. Kent, R. Aebersold, R.A. Barry, P. Tempst, D.B. Teplow, and L.E. Hood A cellular gene encodes scrapie PrP 27-30 protein Cell 40 1985 735 746
3. H.R. Büeler, A. Aguzzi, A. Sailer, R.A. Greiner, P. Autenried, M. Aguet, and C. Weissmann Mice devoid of PrP are resistant to scrapie Cell 73 1993 1339 1347
4. G.A. Wells, A.C. Scott, C.T. Johnson, R.F. Gunning, R.D. Hancock, M. Jeffrey, M. Dawson, and R. Bradley A novel progressive spongiform encephalopathy in cattle Vet Rec 121 1987 419 420
5. C. Weissmann, and A. Aguzzi Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease Curr Opin Neurobiol 7 1997 695 700
6. R.G. Will, J.W. Ironside, M. Zeidler, S.N. Cousens, K. Estibeiro, A. Alperovitch, S. Poser, M. Pocchiari, A. Hofman, and P.G. Smith A new variant of Creutzfeldt-Jakob disease in the UK Lancet 347 1996 921 925
7. R.E. Race, A. Raines, T.G. Baron, M.W. Miller, A. Jenny, and E.S. Williams Comparison of abnormal prion protein glycoform patterns from transmissible spongiform encephalopathy agent-infected deer, elk, sheep, and cattle J Virol 76 2002 12365 12368
8. A. Aguzzi, M. Glatzel, F. Montrasio, M. Prinz, and F.L. Heppner Interventional strategies against prion diseases Nat Rev Neurosci 2 2001 745 749
9. A. Aguzzi, F.L. Heppner, M. Heikenwalder, M. Prinz, K. Mertz, H. Seeger, and M. Glatzel Immune system and peripheral nerves in propagation of prions to CNS Br Med Bull 66 2003 141 159
10. A. Aguzzi Prions and the immune system: a journey through gut, spleen, and nerves Adv Immunol 81 2003 123 171
11. R. Gabizon, M.P. McKinley, D. Groth, and S.B. Prusiner Immunoaffinity purification and neutralization of scrapie prion infectivity Proc Natl Acad Sci USA 85 1988 6617 6621
12. M. Horiuchi, and B. Caughey Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state EMBO J 18 1999 3193 3203
13. D. Peretz, R.A. Williamson, K. Kaneko, J. Vergara, E. Leclerc, G. Schmitt-Ulms, I.R. Mehlhorn, G. Legname, M.R. Wormald, and P.M. Rudd Antibodies inhibit prion propagation and clear cell cultures of prion infectivity Nature 412 2001 739 743
14. M. Enari, E. Flechsig, and C. Weissmann Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody Proc Natl Acad Sci USA 98 2001 9295 9299
15. F.L. Heppner, C. Musahl, I. Arrighi, M.A. Klein, T. Rulicke, B. Oesch, R.M. Zinkernagel, U. Kalinke, and A. Aguzzi Prevention of Scrapie pathogenesis by transgenic expression of anti-prion protein antibodies Science 294 2001 178 182
16. A.R. White, P. Enever, M. Tayebi, R. Mushens, J. Linehan, S. Brandner, D. Anstee, J. Collinge, and S. Hawke Monoclonal antibodies inhibit prion replication and delay the development of prion disease Nature 422 2003 80 83 Chronic passive administration of a monoclonal anti-PrP antibody significantly delayed onset of prion disease in wild-type mice - first successful applied anti-prion regimen in vivo.
17. Polymenidou M, Heppner FL, Pellicioli EC, Urich E, Miele G, Braun N, Wopfner F, Schaetzl H, Becher B, Aguzzi A: Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc Natl Acad Sci USA 2004, in press. One of many recent, disappointing active antiprion immunization approaches that describes the requirements of anti-prion antibodies to potentially confer prionostatic in vivo effects.
18. Roberts WK, Darnell RB: Neuroimmunology of the paraneoplastic neurological diseases. Curr Opin Immunol 2004, 16: in press.
19. M.F. Koller, T. Grau, and P. Christen Induction of antibodies against murine full-length prion protein in wild-type mice J Neuroimmunol 132 2002 113 116
20. E.M. Sigurdsson, D.R. Brown, M. Daniels, R.J. Kascsak, R. Kascsak, R. Carp, H.C. Meeker, B. Frangione, and T. Wisniewski Immunization delays the onset of prion disease in mice Am J Pathol 161 2002 13 17
21. S. Gilch, F. Wopfner, I. Renner-Muller, E. Kremmer, C. Bauer, E. Wolf, G. Brem, M.H. Groschup, and H.M. Schatzl Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells J Biol Chem 278 2003 18524 18531
22. E. Hanan, O. Goren, M. Eshkenazy, and B. Solomon Immunomodulation of the human prion peptide 106-126 aggregation Biochem Biophys Res Commun 280 2001 115 120
23. E. Hanan, S.A. Priola, and B. Solomon Antiaggregating antibody raised against human PrP 106-126 recognizes pathological and normal isoforms of the whole prion protein Cell Mol Neurobiol 21 2001 693 703
24. L. Souan, Y. Tal, Y. Felling, I.R. Cohen, A. Taraboulos, and F. Mor Modulation of proteinase-K resistant prion protein by prion peptide immunization Eur J Immunol 31 2001 2338 2346
25. A. Schwarz, O. Kratke, M. Burwinkel, C. Riemer, J. Schultz, P. Henklein, T. Bamme, and M. Baier Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent Neurosci Lett 350 2003 187 189
26. M.B. Rosset, C. Ballerini, S. Gregoire, P. Metharom, C. Carnaud, and P. Aucouturier Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice J Immunol 172 2004 5168 5174
27. M. Arbel, V. Lavie, and B. Solomon Generation of antibodies against prion protein in wild-type mice via helix 1 peptide immunization J Neuroimmunol 144 2003 38 45
28. Y. Tal, L. Souan, I.R. Cohen, Z. Meiner, A. Taraboulos, and F. Mor Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice J Neurosci Res 71 2003 286 290 The remote prionostatic effect of complete Freund adjuvant (CFA) described in this manuscript challenges earlier reports that claimed the presence of small antiprion effects upon active PrP-immunization when CFA was used as adjuvant.
29. J. Gotter, B. Brors, M. Hergenhahn, and B. Kyewski Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters J Exp Med 199 2004 155 166
30. A. Liston, S. Lesage, J. Wilson, L. Peltonen, and C.C. Goodnow Aire regulates negative selection of organ-specific T cells Nat Immunol 4 2003 350 354 This is a seminal study that demonstrates that peripheral tissue-specific antigens induce central tolerance in the thymus - a process that apparently is controlled by the AIRE gene.
31. J. Sprent, and C.D. Surh Knowing one's self: central tolerance revisited Nat Immunol 4 2003 303 304
32. G.C. Telling, M. Scott, J. Mastrianni, R. Gabizon, M. Torchia, F.E. Cohen, S.J. DeArmond, and S.B. Prusiner Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein Cell 83 1995 79 90
33. Sc and may thus represent a new class of antiprion tools, perhaps also with value in prion diagnostics.
34. S. Sethi, G. Lipford, H. Wagner, and H. Kretzschmar Postexposure prophylaxis against prion disease with a stimulator of innate immunity Lancet 360 2002 229 230
35. M. Heikenwalder, M. Polymenidou, T. Junt, C. Sigurdson, H. Wagner, S. Akira, R. Zinkernagel, and A. Aguzzi Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration Nat Med 10 2004 187 192 This study demonstrates that antiprion effects of CpG-ODN, as reported earlier, are shown to be probably due to extensive lymphoid follicle destruction. The use of CpG-ODN should therefore be considered with caution.
36. M. Prinz, M. Heikenwalder, T. Junt, P. Schwarz, M. Glatzel, F.L. Heppner, Y.X. Fu, M. Lipp, and A. Aguzzi Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion Nature 425 2003 957 962
37. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, and K. Khan Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
38. C. Hock, U. Konietzko, J.R. Streffer, J. Tracy, A. Signorell, B. Muller-Tillmanns, U. Lemke, K. Henke, E. Moritz, and E. Garcia Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease Neuron 38 2003 547 554 Seminal report on the efficacy of Aβ vaccination in interfering with cognitive decline in Alzheimers' patients.
39. F.L. Heppner, J. McLaurin, and S. Gandy Current concepts and future perspectives of Alzheimer's Disease vaccines Alzheimer Dis Assoc Disord 18 2004 38 43
40. C in hippocampal and cerebellar neurons and, subsequently, induces neuronal apoptosis.